Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentadecanoic acid (C15:0) is an essential odd-chain saturated fatty acid recognized for its broad health benefits and pleiotropic mechanisms of action. It acts as a dual partial agonist of peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), an activator of AMP-activated protein kinase (AMPK), and an inhibitor of mammalian target of rapamycin (mTOR), Janus kinase-signal transducer and activator of transcription pathway (JAK-STAT), and histone deacetylase 6 (HDAC6)[1][3][5]. These actions are associated with anti-inflammatory, antifibrotic, anticancer, metabolic-regulating, mitochondrial-repairing, membrane-stabilizing, antimicrobial properties[1][3]. Epidemiological studies link higher circulating levels to reduced risk for cardiometabolic diseases and improved liver function[1][5]. C15:0 is being developed primarily as a dietary supplement to support healthy aging and longevity by targeting cellular processes involved in aging such as inflammation control, mitochondrial function restoration, membrane stability enhancement, glucose metabolism regulation, cholesterol lowering, immune modulation and gut microbiome improvement[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentadecanoic acid.